Entries by Sarah Russo

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.

Authors: C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young
Journal of Psychopharmacology, May 2005

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of can…

,

Cardiovascular pharmacology of cannabinoids.

Authors: P. Pacher, S. Bátkai, G. Kunos
Handbook of Experimental Pharmacology, 2005

Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in…

,

Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.

Authors: J H Allen, G M de Moore, R Heddle, J C Twartz
Gut, November 2004

BACKGROUND AND AIMS: To explore the association between chronic cannabis abuse and a cyclical vomiting illness that presented in a series of cases in South Australia. METHODS: Nineteen patients were identified with chronic cannabis abuse and a cyclical vomiting illness. For le…

The endocannabinoid-CB(1) receptor system in pre- and postnatal life.

Authors: Ester Fride
European Journal of Pharmacology, October 2004

Recent research suggests that the endogenous cannabinoids (“endocannabinoids”) and their cannabinoid receptors have a major influence during pre- and postnatal development. First, high levels of the endocannaboid anandamide and cannabinoid receptors are present in the preimpla…

,

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004

The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…

Prenatal marijuana and alcohol exposure and academic achievement at age 10.

Authors: Lidush Goldschmidt, Gale A Richardson, Marie D Cornelius, Nancy L Day
Neurotoxicology and Teratology, July-August 2004

The effects of prenatal marijuana and alcohol exposure on school achievement at 10 years of age were examined. Women were interviewed about their substance use at the end of each trimester of pregnancy, at 8 and 18 months, and at 3, 6, 10, 14, and 16 years. The women were of l…

Cannabis, cannabinoids and reproduction.

Authors: Boram Park, John M. McPartland, Michelle Glass
Prostaglandins, Leukotrienes and Essential Fatty Acids, February 2004

In most countries Cannabis is the most widely used illegal drug. Its use during pregnancy in developed nations is estimated to be approximately 10%. Recent evidence suggests that the endogenous cannabinoid system, now consisting of two receptors and multiple endocannabinoid li…

Two hundred and thirteen cases of marijuana toxicoses in dogs.

Authors: Pawel Janczyk, Caroline W Donaldson, Sharon M. Gwaltney
Veterinary and Human Toxicology, February 2004

Marijuana (Cannabis sativa) is a commonly used recreational drug among humans; animals may be exposed following ingestion or accidental inhalation of smoke. From January 1998 to January 2002, 213 incidences were recorded of dogs that developed clinical signs following oral exp…

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.

Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003

Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…

,

Cannabinoids reduce symptoms of Tourette’s syndrome.

Authors: Kirsten R Müller-Vahl
Expert Opinion on Pharmacotherapy, October 2003

Currently, the treatment of Tourette’s syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS…